Hexacath, independant European company - Bio Active Coronary Stents

Our company

HEXACATH is an independent European company founded in 1994 in France which develops, manufactures and distributes innovative vascular therapy products dedicated to treat patients affected with myocardial infarction such as a unique Bio Active Coronary Stents (BAS) TiTAN OPTIMAX dedicated to AMI with coronary lesions and the one and only microcirculation catheter RAYFLOW dedicated to AMI without non obstructive coronary arteries.

HEXACATH is a fully integrated company from R&D to distribution.

Innovations in the field of medical technology to treat myocardial infarction with or without coronary lesions is the force driving Hexacath. In-house R&D combined with cutting edge equipment and high tech machines in Hexacath clean rooms allow faster development from the original idea to the final product.

According to the WHO, cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.

Myocardial infarction (MI) usually known as “heart attack” is mainly caused by a blockage preventing blood from flowing to the heart and in this case the most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that supply the heart. Hexacath has targeted this disease developing a unique coronary stent TiTAN OPTIMAX based on a bioactive coating material known as titanium nitride oxide able to reduce both the stent induced thrombosis and restenosis and capable to promote healing post stenting reducing therefore the need for prolonged Dual Anti Platelet Treament (DAPT). In addition, scientists have also discovered that up to 50% of patients with chest pain visiting catheterization laboratories do not present with significant epicardial stenosis meaning this dreadful pathology is caused by something else beyond coronary arteries known as the interventional cardiology Black Box. It took nearly 10 years to Hexacath to develop and patent the RayFlow microcatheter the Key to understand and treat coronary microcirculation dysfunction known as ANOCA (Angina with non obstructive Coronary Arteries) or MINOCA (Myocardial Infarction with Non Obstructive Coronary Arteries).

Our MISSION, is to serve the community of interventional cardiologists to diagnose and treat patientssuffering from myocardial infarction in order to save their lives. To accomplish this goal the Hexacath mission is based on medical device innovations and close partnerships with Key Opinion Leaders cardiologists.